2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Breast Neoplasms
4
Pancreatic Neoplasms
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
101
Etoposide
60
Carboplatin
55
Vincristine
51
Filgrastim
49
Topotecan
44
Temozolomide
44
Melphalan
44
Isotretinoin
44
Doxorubicin
44
Irinotecan
42
Cisplatin
35
3-Iodobenzylguanidine
34
Peripheral Blood Stem Cell Transplantation
31
dinutuximab
30
Granulocyte Colony-Stimulating Factor
30
Radiotherapy
29
sargramostim
28
Granulocyte-Macrophage Colony-Stimulating Factor
25
Busulfan
22
Magnetic Resonance Spectroscopy
19
aldesleukin
18
Thiotepa
18
fludarabine
17
Interleukin-2
17
humanized 3F8 anti-GD2 monoclonal antibody
16
etoposide phosphate
16
naxitamab
15
Ifosfamide
15
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts